Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension

Journal of Cardiovascular Pharmacology

Volumn 41, Issue 6, 2003, Pages 866-869

  Black, Henry R ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

1 adrenergic receptor antagonist; 1 blocker; Anti hypertensive drug; Blood pressure; Combination therapy; Doxazosin; Hypertension

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CALCIUM ANTAGONIST; CHOLESTEROL; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; QUINAPRIL;

ARTICLE; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HEADACHE; HEALTH CARE COST; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID BLOOD LEVEL; LIPID METABOLISM; PRIORITY JOURNAL; VERTIGO;

ANTIHYPERTENSIVE AGENTS; DOXAZOSIN; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; MALE; RANDOMIZED CONTROLLED TRIALS;

EID: 0037780752     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200306000-00006     Document Type: Article

References (29)

1. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291-7.
2. The sixth report of the Joint National Committee (JNC-VI) on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-46.
3. Chalmers J. The 1999 WHO-ISH Guidelines for the Management of Hypertension. Med J Aust. 1999;171:458-459
4. MacConnachie A, Maclean D. Low dose combination antihypertensive therapy: additional efficacy without additional adverse effects? Drug Saf. 1995;12:85-90.
5. Feher M, Henderson A, Wadsworth J, et al. Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension - results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects. J Hum Hypertens. 1990;4:571-7.
6. Fulton B, Wagstaff A, Sorkin E. Doxazosin: an update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs. 1995;49:295-320.
7. Grimm RJ, Flack J, Grandits G, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA. 1996;275:1549-56.
8. Shionoiri H, Gotoh E, Ito T, et al. Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: a multicenter prospective study. Am J Med Sci. 1994;307(suppl 1):S91-5.
9. Giorda C, Appendino M, Mason MG, et al. Alpha 1-blocker doxazosin improves peripheral insulin sensitivity in diabetic hypertensive patients. Metabolism. 1995;44:673-6.
10. Taylor S. Clinical pharmacotherapeutics of doxazosin. Am J Med. 1989;87(suppl 2A):2S-11S.
11. Brown MJ, Dickerson JE. Synergism between alpha 1-blockade and angiotensin converting enzyme inhibition in essential hypertension. J Hypertens Suppl. 1991;9(6):S362-3.
12. Donnelly R, Elliott HL, Meredith PA, et al. Combination of nifedipine and doxazosin in essential hypertension. J Cardiovasc Pharmacol. 1992;19: 479-86.
13. Lindner UK, von Manteuffel GE, Stafunsky M. The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine. Am Heart J 1988;116(6 Pt 2):1814-20.
14. ++ blockade: a new combination for the treatment of hypertension [abstract]. From Proceedings of the BPS, January 5-7, 1994. Br J Clin Pharmacol. 1994;37:474P.
15. Englert RG, Barlage U. The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by beta-blockers. Am Heart J. 1991;121(1 Pt 2):311-6.
16. Searle M, Dathan R, Dean S, et al. Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicenter trial. Eur J Clin Pharmacol. 1990;39:299-300.
17. Stokes GS, Johnston HJ, Okoro EO, et al. Comparative and combined efficacy of doxazosin and enalapril in hypertensive patients. Clin Exp Hypertens. 1994;16:709-27.
18. Bainbridge A, Meredith P, Elliott H. A clinical pharmacological assessment of doxazosin and enalapril in combination. Br J Pharmacol. 1993; 36:599-602.
19. Englert RG, Mauersberger H. A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy. Am Heart J. 1988;116(6 Pt 2):1826-32.
20. Troffa C, Manunta P, Dessi-Fulgheri P, et al. Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension. Curr Ther Res. 1994;55:22-31.
21. Maclean D, McDevitt DG. Doxazosin in 'resistant' hypertension. J Hum Hypertens. 1990;4(suppl 3):50-1.
22. Mann SJ, Gerber LM. Low-dose alpha/beta blockade in the treatment of essential hypertension. Am J Hypertens. 2001;14(6 Pt 1):553-8.
23. Rachmani R, Levi Z, Slavachevsky I, et al. Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria: a randomized cross-over study. Nephron. 1998;80:175-82.
24. Nalbantgil S, Nalbantgil I, Onder R. Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension. Am J Hypertens. 2000;13:921-6.
25. Black H, Sollins J, Garofalo J. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study. Am J Hypertens. 2000;13:468-74.
26. Martell N, Luque M. Doxazosin added to single-drug therapy in hypertensive patients with benign prostatic hypertrophy. J Clin Hypertens (Greenwich). 2001;3:218-23.
27. Hunter Hypertension Research Group. Combined effect of doxazosin and pindolol on blood pressure control and lipid concentrations in patients with essential hypertension selected from general practice. J Hum Hypertens. 1992;6:181-4.
28. Marti-Canales JC, Ceballos R, Puerta-Jiminez LM, et al. Comparative study of doxazosin and hydrochlorothiazide when added to nonresponders to ARBII losarthan therapy [abstract]. Am J Hypertens. 2001;14(suppl 4):A177.
29. Chung M, Vashi V, Puente J, et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol. 1999;48:678-87.